Pfizer Inc. $PFE Shares Sold by Marathon Capital Management

Key Points

• Marathon Capital Management cut its Pfizer stake by 82.9% in Q3, selling 82,475 shares and leaving 17,035 shares valued at about $434,000 per its latest 13F filing.
• Wall Street sentiment is largely neutral — Pfizer has a consensus rating of "Hold" with an average price target of $28.05 after several firms trimmed ratings and targets.
• Pfizer beat Q4 estimates (EPS $0.66 vs. $0.57; revenue $17.56B vs. $16.93B) but still faces headwinds from post‑COVID revenue normalization and drug‑pricing pressure even as pipeline and commercial positives (China GLP‑1 approval, new immunology/oncology data) provide potential upside.

Marathon Capital Management decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 82.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,035 shares of the biopharmaceutical company's stock after selling 82,475 shares during the quarter. Marathon Capital Management's holdings in Pfizer were worth $434,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Mangrove Partners IM LLC acquired a new stake in Pfizer during the third quarter worth about $844,000. Siemens Fonds Invest GmbH boosted its holdings in Pfizer by 3.9% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 230,597 shares of the biopharmaceutical company's stock valued at $5,876,000 after purchasing an additional 8,560 shares during the last quarter. NorthRock Partners LLC boosted its holdings in Pfizer by 14.7% in the 3rd quarter. NorthRock Partners LLC now owns 76,478 shares of the biopharmaceutical company's stock valued at $1,949,000 after purchasing an additional 9,827 shares during the last quarter. Prudential PLC grew its stake in shares of Pfizer by 0.3% in the 3rd quarter. Prudential PLC now owns 793,527 shares of the biopharmaceutical company's stock valued at $20,219,000 after buying an additional 2,600 shares during the period. Finally, Texas Capital Bancshares Inc TX purchased a new stake in shares of Pfizer in the 3rd quarter valued at approximately $64,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Daiwa Securities Group lowered shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an "underperform" rating in a research report on Wednesday, December 17th. Cantor Fitzgerald reissued a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Morgan Stanley reduced their target price on Pfizer from $32.00 to $28.00 and set an "equal weight" rating on the stock in a research report on Friday, December 12th. Finally, Bank of America decreased their price target on Pfizer from $29.00 to $28.00 and set a "neutral" rating on the stock in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $28.05.

Pfizer Trading Down 1.0%

NYSE PFE opened at $26.60 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The firm has a 50 day moving average of $26.50 and a two-hundred day moving average of $25.52. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue was down 1.2% on a year-over-year basis. During the same period last year, the business earned $0.63 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla somatrogon: Pfizer Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.